Cardiomems Net Worth (Updated 2026).

Cardiomems, a pioneering company in the medical device industry, was founded in 2007 by a group of visionary engineers and cardiologists. Their mission was clear: to improve the lives of heart failure patients by developing innovative, minimally invasive solutions that could monitor and treat heart conditions more effectively than ever before.

The company’s breakthrough came with the development of its wireless, implantable heart failure diagnostic system. This groundbreaking technology, approved by the FDA in 2010, allowed for real-time monitoring of a patient’s heart condition, providing clinicians with crucial data to manage heart failure more proactively. This innovation not only revolutionized the way heart failure was managed but also catapulted Cardiomems into the limelight, establishing it as a leader in the field of heart failure management.

Cardiomems’ Net Worth in 2025

As of 2025, Cardiomems’ net worth is estimated to be around $10 million, according to the latest available information.

Career

Cardiomems, born Belcalis Marlenis Almánzar, is a renowned rapper, singer, and songwriter from the Bronx, New York. She rose to fame in 2015 with her mixtape “Gangsta Bitch Music, Vol. 1” and gained further recognition with her 2016 single “Bodak Yellow,” which topped the Billboard Hot 100 chart. She has since released multiple successful albums and singles, earning numerous awards and nominations.

Other Ventures

In addition to her music career, Cardiomems has ventured into various business endeavors. She has launched her own clothing line, “Bardi Beauty” with Kylie Cosmetics, and a successful shoe collection with Steve Madden. She has also collaborated with Fashion Nova on a clothing line and has her own line of dolls with Mattel. Additionally, she has invested in various tech startups and has a stake in a whiskey brand, “Star Schnapps.”

Assets

Cardiomems’ assets include several luxury cars such as a Lamborghini Urus, a Bentley Bentayga, and a Rolls-Royce Cullinan. She also owns multiple properties, including a mansion in Atlanta and a penthouse in New York City. Her jewelry collection, which includes several expensive pieces, is also a significant asset. Additionally, she holds valuable intellectual property rights to her music and brand.

Annual Income

Cardiomems’ annual income is primarily derived from her music career, including album sales, streaming royalties, and touring. She also earns substantial income from her various business ventures and endorsements. According to Forbes, her 2021 earnings were estimated to be around $40 million, making her one of the highest-paid female rappers of the year.

Frequently Asked Questions about  Cardiomems

Frequently Asked Questions: Cardiomems Net Worth

1. What is Cardiomems?

Cardiomems is a medical device company that specializes in the development of implantable wireless sensors for the monitoring of heart failure patients.

2. When was Cardiomems founded?

Cardiomems was founded in 2007.

3. Who are the founders of Cardiomems?

The founders of Cardiomems are Bruce Satchwell and Mark Day. They are both experienced entrepreneurs in the medical device industry.

4. What is the latest estimated net worth of Cardiomems?

The latest estimated net worth of Cardiomems is $1 billion.

5. How has Cardiomems grown over the years?

Cardiomems has grown significantly over the years, expanding its product portfolio and geographic reach. It has also secured several rounds of funding from investors, including venture capital firms and strategic partners.

6. What are some of the products developed by Cardiomems?

Cardiomems has developed several products, including the HeartLogic Heart Failure Diagnostic Service and the CardioMEMS HF System, which is an implantable wireless sensor that measures pulmonary artery pressure.

7. Who are the competitors of Cardiomems?

Some of the competitors of Cardiomems include Medtronic, Boston Scientific, and Abbott Laboratories, among others.

8. How does Cardiomems generate revenue?

Cardiomems generates revenue through the sale of its products, primarily the CardioMEMS HF System, to hospitals and healthcare providers.

9. What is the market size for heart failure monitoring devices?

The global market for heart failure monitoring devices is expected to reach $11.5 billion by 2027, growing at a CAGR of 9.5% during the forecast period.

10. What is the future outlook for Cardiomems?

The future outlook for Cardiomems is positive, with the company continuing to invest in research and development to expand its product offerings and geographic reach. The company is also exploring strategic partnerships and collaborations to further its growth.